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Evaluation of fibrin based gene-activated matrices for BMP2/7 
plasmid co-delivery in a rat non-union model 
 
 
 
ABSTRACT 
 
PURPOSE: Treatment of large segmental bone defects still is a challenge in clinical routine. 
Application of Gene-activated matrices (GAMs) based on fibrin, BMP 2/7 plasmids and non-
viral transfection reagents (cationic polymers) could be an innovative treatment strategy to 
overcome this problem. 
The aim of this study was to determine the therapeutic efficacy of fibrin GAMs with or 
without additional transfection reagents for bone morphogenic protein (BMP)2 and BMP7 
plasmid co-delivery in a rat femur non-union model. 
METHODS: In this experimental study a critical size femoral defect was created in 27 rats. At 
4 weeks after the surgery animals were separated into 4 groups and underwent a second 
operation. Fibrin clots containing BMP2 and BMP7 plasmids with and without cationic 
polymer were implanted into the femoral defect. Fibrin clots containing recombinant human 
(rh) BMP2 served as positive and clots without supplement as negative controls.  
RESULTS: At 8 weeks animals which received GAMs containing the cationic polymer and 
BMP 2/7 plasmids showed decreased bone volume compared to animals treated with GAMs 
and BMP2/7 only. Application of BMP2 and BMP7 plasmids in fibrin GAMs without 
cationic polymer lead to variable results. Animals which received rhBMP 2 protein showed 
increased bone volume and osseous unions were achieved in 2 out of 6 animals.    
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CONCLUSIONS: Cationic polymers decrease therapeutic efficiency of fibrin GAM based 
BMP2/7 plasmid co-delivery in bone regeneration. Non-viral gene transfer of BMP2/7 
plasmids needs alternative promoters (e.g. by sonoporation, electroporation) to promise 
beneficial clinical effects.  
 
 
INTRODUCTION 
 
Treatment of large segmental bone defects still is a challenge in clinical routine. In the last 
years the U.S. Drug and Food Administration approved the clinical use of recombinant human 
(rh) BMP2 and BMP7 for special indications and provided an innovative tool in the treatment 
of substantial bone defects[1]. Despite encouraging results in clinical routine therapy costs 
still are high and the local use of highly increased BMP concentrations raises safety 
concerns[2]. An alternative strategy is the delivery of BMP transgenes instead of recombinant 
growth factors in order to generate a local sustained release of host-cell produced, highly 
bioactive growth factors[3-6]. Recent experimental data showed a synergistic effect of BMP2 
and BMP7 therapeutic gene co-delivery[7-9]. This promises to increase therapeutic efficiency 
in upcoming clinical studies. Such Gene therapeutic approaches could increase the efficiency 
of BMPs and reduce costs as well as potential side effects. Viral delivery of DNA vectors to 
the target tissue was shown to be highly effective but could result in a fatal immune response 
of the host[10,11]. In contrast non-viral gene transfer using plasmids is regarded as a 
relatively safe but inefficient strategy[12,13]. 
Therefore, several strategies have been developed to overcome barriers to non-viral gene 
delivery and to enhance transfection efficacies[14,15]. The use of cationic polymers or 
lipoplexes and other reagents for non-viral gene delivery is a well established method which 
can significantly increase transfection efficacies in vitro and in vivo[16-18]. In recent years 
 3 
several studies succeeded to increase passive gene transfer by lipofection or cationic polymer 
based gene delivery in animal models: Critical size mandibular defects in rats were 
successfully treated by liposome-mediated gene transfer of BMP2 in an ex vivo setting[19]. In 
vivo experiments showed increased bone formation and osseointegration when using 
liposomal BMP2 vectors in calvaria defects in pigs[20]. Using fibrin based gene-activated 
matrices (GAMs) is another strategy which showed promising results in promoting passive 
gene transfer[21]. A previous in vivo study assessed wound healing in an epigastric flap rat 
model. Animals treated with VEGF plasmids and GAMs consisting of fibrin and 
lipofectamine showed increased vascularisation and flap survival compared to the control 
groups[22]. Up to now there is no study focusing on the effects of transfection-reagent 
enhanced in vivo co-delivery of BMP2 and BMP7 plasmids in GAMs in a segmental bone 
defect model.  
Therefore, the aim of this study was to determine the therapeutic efficacy of fibrin GAMs 
with or without additional poly(hydroxyalkylene)imine (PEI) cationic transfection reagents 
for bone morphogenic protein (BMP)2 and BMP7 plasmid co-delivery in a rat femur non-
union model. 
 
 
MATERIALS AND METHODS 
 
BMP2 and BMP7 plasmids 
Preparation and in vitro testing of the BMP2 and BMP7 plasmids are described 
elsewhere[23]. The plasmids were amplified in E.coli TOP10 (Life Technologies Ltd, Paisely, 
UK, ♯C404003) and isolated as endotoxin-free maxipreps using the EndoFree Plasmid Maxi 
or Giga kits (Quiagen GmbH, Hilden, Germany, ♯12362). (for plasmid maps, see Fig.1).  
 
 4 
Experimental protocol 
 
All experiments performed in this study were approved by the Animal Protocol Review Board 
of the City Government of Vienna. Animals were maintained and treated in accordance with 
the requirements of the Guide for the Care and Use of Laboratory Animals of the National 
Institutes of Health (DHHS Publikation NIH 86-23, 1985). We used a critical size defect 
model in rat femurs which was previously validated including biomechanical testing and 
micro CT analysis[24]. We studied male Spraque-Dawley rats at an age of 20 to 24 weeks 
weighing at least 350 g. The animals were randomized and separated into four groups (n=6-
9). All animals underwent surgery to create a standardized critical sized defect (3.8 mm) of 
the right femur. A silicone spacer was placed into the defect to avoid formation of 
vascularized scar tissue. At four weeks all animals underwent a second surgery. The silicone 
spacer was removed. The defect was filled with fibrin clots (V=160 µl), which served as gene 
activated matrix (GAM) for all groups. Beneficial effects using fibrin as GAM for gene 
delivery was extensively studied and previously published[21,22]. 
The fibrin sealant (Tisseel®, Baxter AG, Vienna, Austria) was prepared according to 
manufacturer’s recommendations. 31.25 µl of fibrinogen, 31.25 µl of thrombine 
(c=400IU/mL) and supplements (recombinant human BMP2, BMP2/7 Plasmids, cationic 
polymer) were mixed in an Eppendorf tubecap under sterile conditions. Saline was added up 
to a volume of 160 µl. The fibrin clot was allowed to solidify at 37°C for 5 minutes before 
implantation. 
In the first group (FIBRIN, n=6) animals received a fibrin clot without supplement. In the 
second group (rhBMP2, n=6) animals received a fibrin clot containing 10 µg recombinant 
human BMP2 (InductOS®, Pfizer, Vienna, Austria). In the third group (BMP2/7, n=9) 
animals received a fibrin clot containing 20 µg BMP2 and 20 µg BMP7 plasmid vectors. In 
the fourth group (PEI_BMP2/7, n=6) animals received a fibrin clot containing 20 µg BMP2 
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plasmids, 20 µg BMP7 plasmids and 40 µl poly (hydroxyalkylene) imine (Turbofect®, 
Thermo Scientific Inc., Vilnius, Lithuania[25]). At 8 weeks all animals were sacrificed and 
union rate, bone volume and bone density was determined.  
  
Surgical Procedure 
Animals were anaesthetized by intramuscular injection of ketamine hydrochloride (110 mg 
/kg body weight; Ketamidor, Richter Pharma, Austria) and xylazine hydrochloride (12 mg /kg 
body weight; Rompun, Bayer Healthcare, Germany). Each rat
 
was placed on a thermostatic 
heating plate in a lateral decubitus position. A lateral approach was used to expose the 
femoral shaft. A 2 mm 5-hole AO titanium plate was fixed onto the anterolateral surface of 
the femur using 4 AO cortical screws (Synthes, Swizerland). A 3.8 mm segmental bone defect 
was created by double osteotomy in the the femur´s midshaft using a reciprocating saw 
(CORE Reciprocating Saw, Stryker Instruments, USA) under guidance of a template. To 
simulate a delayed union the femoral gap was filled with a 3.8 mm silicone spacer, which was 
firmly sutured onto the plate. The wound was closed in two layers and animals were allowed 
free movement. Analgesia was postoperatively provided by subcutaneous administration of 
meloxicam (0.15 mg /kg body weight; Metacam, Boehringer Ingelheim, Germany) for four 
days. 
At four weeks all animals underwent a second intervention. The segmental bone defect was 
exposed through a small skin incision under anaesthesia. The silicone spacer was removed 
and the proximal and distal femoral bony edges were debrided using a burr (CORE Micro 
Drill, Stryker Instruments, USA) under constant irrigation with physiologic saline solution. 
After creating bleeding bony surfaces fibrin clots with or without supplements were applied 
according the experimental protocol. The wound was closed by layers. 
At 8 weeks anaesthetized animals were sacrificed. The right femurs were explanted for further 
measurements. The surrounding soft tissue was removed and the specimens were fixed in 4% 
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neutral buffered formalin for further radiological and histological assessments. 
 
Imaging  
 
For assessment of union rate and bone volume, the femura were explanted and the titanium 
plate and screws were replaced by a synthetic radiolucent device. The bone was scanned using 
a microtomographic system (µCT 20; Scanco Medical, Zurich, Switzerland) between 2mm 
proximal and distal of the defect. A 3D image was reconstructed using 100 horizontal micro 
CT slide images 30 µm thick giving a resolution of 20 µm. Bone tissue was isolated using an 
automatic threshold procedure. The callus cross-sectional area was assessed in an 
interfragmentary horizontal slice.  
In a first step all rat femurs were classified. Specimens exhibiting a visible bony bridge which 
increased 30% of the total cross sectional defect area were defined as unions. Bony bridges 
below 30% were defined as narrow unions. Specimens without new bone formation in the 
defect area were classified as oligotrophic or atrophic non unions according to Weber and 
Cech[26]. In a second step we performed a quantitative analysis of newly formed bone within 
the defect area. Bone volume was expressed in mm
3
 per defect. 
 
Histology 
 
After completing the radiological measurements, rat bone specimens were fixed in 4% neutral 
buffered formalin for 48h and rinsed in tap water overnight. After that, specimens were 
submitted to a quick decalcification with an agent containing 14% hydrochloric acid (New 
decalc
®
, Medite, Burgdorf, Germany) and subsequently rinsed with running tap water 
overnight. 
Decalcified bone samples were dehydrated and embedded in paraffin, and 4 µm sections were 
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cut on a rotary microtome. The paraffin sections were deparaffinized in xylene, rehydrated in 
graded alcohols, and stained with hematoxylin & eosin (H&E). 
 
Statistics 
 
All data (except the percentage of bone union) are presented as median ± interquartile range. 
Statistical analysis was performed using a standard software package (Graph Pad Prism, 
Graph Pad Software Inc., CA, USA). Normal distribution of data was tested by the 
Kolmogorov-Smirnov test. Groups were compared using one-way ANOVA. Post test was 
performed using the Tukey´s Multiple Comparison test. P-values less than 0.05 were 
considered statistically significant. 
 
 
RESULTS 
 
Union Rate  
Union rate was assessed 8 weeks after creation of the femoral critical size defect and 4 weeks 
after implantation of the fibrin clots containing plasmids with/without cationic polymer. 
Unions were classified according the system of Weber and Cech[26]. 
Osseous unions were found in two out of six animals in the rhBMP2 group. Further two 
animals in this group showed narrow unions. Oligotrophic non unions were found in one out 
of six animals in the FIBRIN group, three out of nine animals in the BMP2/7 group and two 
out of six animals in the rhBMP2 group (see Fig.2). 
 
Bone volume 
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Bone volume within the critical size defect was determined in all 27 treated rat femurs (see 
Fig. 3). Animals in the PEI_BMP2/7 group showed significantly decreased bone volume 
compared to the rhBMP2 (p < 0.01) and the BMP2/7 (p < 0.05) group. Animals in the 
rhBMP2 group showed significantly increased bone volume compared to the FIBRIN (p < 
0.05) and the PEI_BMP2/7 group (p < 0.01). There was no significant difference comparing 
bone volume in the rhBMP2 and the BMP2/7 group. 
 
Histological findings 
Rat femur sections were subjected to H&E staining to analyze tissue characteristics and bone 
quality. Representative histological specimens of each group are presented (see Fig. 4A-D). 
Samples in the FIBRIN group showed tight fibrous tissue filling up the gap. Signs of incipient 
osteogenesis were found on one defect margin adjacent to the former plate location. In 
contrast samples in the rhBMP2 group showed extended bone formation within the defect. 
Lamellar bone in cortical regions and woven bone in the medullary region predominated the 
histological sections. Samples in the BMP2/7 group showed distinctive callus formation 
featuring extended osteogenic areas as well as cartilaginous tissues within the defect. 
Sufficient bony bridging was not achieved in any of the specimens. Samples in the 
PEI_BMP2/7 group missed any signs of bone formation. The defect was filled up with loose 
fibrous tissue. Osteogenic or chondrogenic precursor cells were absent.        
 
 
DISCUSSION 
 
In the present study we assessed the effects of PEI based cationic polymers and fibrin GAMs 
on passive gene transfer of BMP2 and BMP7 plasmids in a femoral non-union rat model. 
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The main finding of the study presented herein was a detrimental effect of the cationic 
transfection reagent on union rate and bone formation in vivo. Coadministration of cationic 
polymer for transfection in fibrin GAMs failed to enhanced the therapeutic effect in the 
experiments. In the PEI_BMP2/7 group 6 out of 6 femurs showed atrophic non unions (see 
Fig. 2). Bone volume in this group was significantly decreased compared to animals treated 
with BMP2 and BMP7 plasmids without cationic polymer (see Fig. 3). Histological sections 
showed absence of chondrogenic or osteogenic cells (see Fig. 4D). On one hand this finding is 
remarkable as there are previous studies showing beneficial effects of additional reagents such 
as liposomes[19,20] or polyethyleneimine based cationic polymers on BMP gene delivery and 
bone regeneration[20,19,27,28]. Administration of a BMP2 plasmid in combination with 
lipoplexes increased bone formation and osseointegration in a rat and pig[20,19] model. On 
the other hand it is well established that liposomal reagents as well as cationic reagents exhibit 
cytotoxic effects in a dose dependent manner. In cell cultures administration of lipoplexes 
caused cell shrinking, decreased mitose rates and vacuolisation of the cytoplasm. Beyond that 
there is evidence of interaction with the immune mediated cytokine cascade. In vivo 
administration of lipoplexes led to local and systemic inflammation. Blood cell agglutination 
was caused due to the positive charge of the lipids and resulted in local microinfarction and 
vascular inflammatory response[17,18]. In vitro tests overcome this problem by using 
tumorous cell lines, which are held under optimal conditions. Cell loss due to the cytotoxic 
effects of lipoplexes or cationic polymers can be accepted in certain cases, especially in vitro 
where high cell numbers are employed for transfection. In contrast our two-step surgery 
model of an atrophic non union provides a limited number of osteogenic precursor cells and a 
situation of compromised vascularisation. It is possible that the negative effects of the 
addition of the cationic polymer in this study are a consequence of the cytotoxic effects of PEI 
on the limited amount of host progenitor cells required for transgene expression and 
regeneration in this clinically relevant animal model. 
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Another important finding of this study is the insignificant therapeutic effect of passive gene 
transfer when administering exclusive BMP2 and BMP7 plasmids. 3 out of 9 animals in the 
BMP2/7 group showed oligotrophic non unions. Histological sections showed extensive areas 
of incipient osteogenesis without sufficient new bone formation (see Fig. 5B). There was 
however a tendency of increased bone volume in the BMP2/7 group compared to the negative 
control (Fibrin group). Nevertheless, inconsistent results due to single outliers failed to show 
statistically significant differences. This insignificant therapeutic effect was found in 
numerous studies, which demonstrated non-viral gene transfer as a safe but relative inefficient 
strategy to increase bone growth[10,12,13]. Results of this study highlight the importance of 
promoting non-viral gene transfer by alternative methods. Currently sonoporation or 
electroporation seem to be the most promising strategies in terms of safety, efficacy and 
minimal invasiveness[9,29-31]. Further studies are needed to clarify if those strategies are 
capable to increase bone growth in a clinical relevant segmental bone defect model.  
As a positive control animals in the rhBMP2 group were treated by application of 
recombinant growth factor. Without any surprises animals showed increased bone volume 
compared to the Fibrin and PEI_BMP2/7 group. As a consequence osseous unions as well as 
narrow unions occurred in 2 out of 6 animals respectively. The results are supported by a 
previous study[32]. 
 
In conclusion, the addition of PEI-based cationic polymers to fibrin GAMs failed to promote 
non-viral gene transfer of BMP2 and BMP7 plasmids in this study. Application of BMP2 and 
BMP7 plasmids in fibrin GAMs without cationic polymer lead to variable results in bone 
volume without sufficient new bone formation to bridge the femoral critical size defect. It 
indicates a potential advantage of delivering BMP2 and 7 transgenes in fibrin gels for tissue 
regeneration if enhanced by methods such as the recently developed matrix-assisted 
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sonoporation[33] or methods without application of biomaterials relying only on physical 
stimuli for gene delivery such as sonoporation or electroporation[9,31]. 
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FIGURE CAPTIONS 
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Fig. 1: Constitutive BMP2 and BMP7 expression plasmids: pVAX1-BMP2 and pVAX1-
BMP7.  
 
 
Fig. 2: Union rate at 4 weeks following treatment of a 3.8mm critical size femoral defect (%). 
Black and grey areas represent unions and narrow unions respectively. Black/white stripped 
and white areas represent oligotrophic and atrophic non unions respectively. 
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Fig. 3: Bone volume at 4 weeks following treatment of a 3.8 mm critical size femoral defect 
(mm
3
). * indicates p<0.05, ** indicates p<0.01. Data are presented as median ± interquartile 
range. 
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Fig. 4: Histological sections at 4 weeks following treatment of a 3.8 mm critical size femoral 
defect (H&E staining, magnification x10). A: Samples in the FIBRIN group show tight 
fibrous tissue filling up the gap. Signs of incipient osteogenesis are found on one defect 
margin adjacent to the former plate location. B: In contrast samples in the rhBMP2 group 
show extended bone formation within the defect. Lamellar bone in cortical regions and woven 
bone in the medullary region predominate the histological sections. C: Samples in the 
BMP2/7 group show distinctive callus formation featuring extended osteogenic areas as well 
as cartilaginous tissues within the defect. Sufficient bony bridging is not achieved in any of 
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the specimens. D: Samples in the PEI_BMP2/7  group miss any signs of bone formation. The 
defect is filled up with loose fibrous tissue. Osteogenic or chondrogenic precursor cells are 
absent. 
